Provided by Tiger Trade Technology Pte. Ltd.

Insmed

125.77
+0.69000.55%
Post-market: 125.770.00000.00%19:30 EDT
Volume:1.12M
Turnover:141.84M
Market Cap:27.47B
PE:-30.76
High:127.20
Open:125.22
Low:124.82
Close:125.08
52wk High:212.75
52wk Low:90.39
Shares:218.38M
Float Shares:216.82M
Volume Ratio:0.67
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0882
EPS(LYR):-6.4200
ROE:-87.22%
ROA:-22.17%
PB:36.26
PE(LYR):-19.59

Loading ...

Insmed to Release Q2 2026 Results, Host Investor Conference Call

Reuters
·
Jul 23

Insmed (INSM) Stock Could Be Pricey As Its 4.4x Run Continues

Simply Wall St.
·
Jul 22

Guggenheim Reaffirms Their Buy Rating on Insmed (INSM)

TIPRANKS
·
Jul 22

Ritu Baral Reaffirms Buy on Insmed, Raising Price Target from $200 to $243 Ahead of Q2 Preview

TIPRANKS
·
Jul 22

Insmed initiated with an Outperform at BMO Capital

TIPRANKS
·
Jul 21

Is Insmed (INSM) Undervalued After Positive TPIP Data Backed A Phase 3 Push?

Simply Wall St.
·
Jul 20

Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3

Simply Wall St.
·
Jul 19

Analysts’ Top Healthcare Picks: Insmed (INSM), Illumina (ILMN)

TIPRANKS
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), AbCellera Biologics (ABCL) and DBV Technologies SA – American (DBVT)

TIPRANKS
·
Jul 17

Insmed Announces Positive 12-Month TPIP PAH Data

TIPRANKS
·
Jul 17

Matt Phipps Reiterates Buy on Insmed, Citing Strong TPIP PAH Data, Solid Brinsupri/Arikayce Growth, and Overdone Share Pullback

TIPRANKS
·
Jul 17

Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients

MT Newswires Live
·
Jul 16

Insmed’s inhalation powder shows efficacy and safety in arterial hypertension

TIPRANKS
·
Jul 16

Insmed Reports Positive 12-month TPIP Extension Data in Pulmonary Arterial Hypertension Study

Reuters
·
Jul 16

Insmed - Tpip Safe and Well-tolerated with no New Safety Signals Through Month 12

THOMSON REUTERS
·
Jul 16

Insmed Announces Positive 12-month Data from the Ongoing Open-label Extension Study of Treprostinil Palmitil Inhalation Powder (tpip) in Patients with Pulmonary Arterial Hypertension

THOMSON REUTERS
·
Jul 16

Insmed - Placebo Crossed Group on Tpip Achieves Similar Outcomes to Tpip Continued Group at 12 Months

THOMSON REUTERS
·
Jul 16

Insmed - Tpip Demonstrates Sustained Improvement and Reduced Mortality Risk at 12 Months

THOMSON REUTERS
·
Jul 16

Insmed is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 15

Barclays Remains a Buy on Insmed (INSM)

TIPRANKS
·
Jul 13